Found 9 Ulcers trials
A listing of Ulcers medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (TOP-N53-02)
The main goal of this clinical trial is to learn about how safe the new drug TOP-N53 solution is when it is applied to open wounds on the fingertip (digital ulcers) in people with an uncommon illness that results in hard, thickened areas of skin and additional problems with internal …
A Prospective Multicenter Non-Blinded Non-Randomized Study of the Relay PRO Thoracic Stent-Graft in Subjects with Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
The primary safety objective is a composite of the number of Major Adverse Events (MAEs) occurring through 30 days post-procedure compared to the rate in subjects treated with the Relay Thoracic Stent-Graft in the U.S. Pivotal Trial (P110038). The primary effectiveness objective is a composite of the number of effectiveness …
Boomerang Early Feasibility Study
The purpose of this research study is to learn more about the safety and performance of SNS when used in patients who have Crohn’s disease or left-sided ulcerative colitis. The InterStim™ Neurostimulator (InterStim) will be used in every participant who agrees to participate and meets all the eligibility criteria for …
A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
The study will enroll subjects who have completed Study M16-067 or Study M16-065 and have achieved clinical response, defined as decrease from Baseline of induction study of Adapted Mayo score greater than or equal to 2 points and greater than or equal to 30%, PLUS a decrease in rectal bleeding …
A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
A Phase 2 Multi-center Randomized Double-Blind Placebo-Controlled Dose Range Finding Study to Evaluate the Safety Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects who have Diabetic Foot Ulcer with Peripheral Arterial Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have DFU with PAD. The study will enroll approximately 24 subjects. Two dose levels of PDA-002 (3 x 106 and 30 x 106 cells) versus placebo will be evaluated in 1:1:1 randomization approach. Subjects will …
EVALUATION OF THE VALIANT MONA LSA THORACIC STENT GRAFT SYSTEM IN DESCENDING THORACIC AORTIC ANEURYSMS AND CHRONIC DISSECTIONS
The trial involves an investigational device (not approved by the FDA) for subjects who have an aneurysm (bulge), dissection (tear) or a penetrating ulcer (bubble) of the descending aorta that involve an artery (main blood vessel in your body). The subject must need to have one of their blood vessels …
A OBSERVATIONAL STUDY TO EVALUATE THE ASSOCIATION BETWEEN HISTOLOGICAL REMISSION AND LONG-TERM OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS
To evaluate the association between histological remission and a composite outcome of colectomy, IBD-related hospitalization, or intravenous corticosteroid use
DECODE Biologic-Describing the Consequences of Delays in Biologic initiation Study
This study plans to learn more about the usage and effect of biologic medications with patients that have inflammatory bowel disease (IBD). IBD includes both Crohn’s Disease (CD) and Ulcerative Colitis (UC), which currently affects around 1.5 million Americans. Medical therapies for IBD focus on reducing the inflammation of the …
Please choose between Voice or SMS based delivery of verification code
or